<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<style type="text/css">
.txt { white-space:nowrap; }
#f0 { font-family:sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff0; src: url("0.ttf"); }
#f1 { font-family:ff0,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff1; src: url("1.ttf"); }
#f2 { font-family:ff1,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff2; src: url("2.ttf"); }
#f3 { font-family:ff2,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff3; src: url("3.ttf"); }
#f4 { font-family:ff3,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff4; src: url("4.ttf"); }
#f5 { font-family:ff4,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff5; src: url("5.ttf"); }
#f6 { font-family:ff5,sans-serif; font-weight:bold; font-style:normal; }
</style>
</head>
<body>
<img id="background" style="position:absolute; left:0px; top:0px;" width="595" height="842" src="page1.png">
<div class="txt" style="position:absolute; left:412px; top:30px;"><span id="f3" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">기업 </span><span id="f6" style="font-size:14px;vertical-align:baseline;color:rgba(0,0,0,1);">Note</span></div>
<div class="txt" style="position:absolute; left:412px; top:59px;"><span id="f6" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">2018. 4. 9</span></div>
<div class="txt" style="position:absolute; left:38px; top:136px;"><span id="f3" style="font-size:27px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스</span><span id="f3" style="font-size:21px;vertical-align:baseline;color:rgba(0,0,0,1);">(207940)</span></div>
<div class="txt" style="position:absolute; left:38px; top:202px;"><span id="f3" style="font-size:14px;vertical-align:baseline;color:rgba(0,0,0,1);">유럽, Humira, first-mover, 성공적</span></div>
<div class="txt" style="position:absolute; left:412px; top:173px;"><span id="f3" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">매수(유지)</span></div>
<div class="txt" style="position:absolute; left:412px; top:203px;"><span id="f3" style="font-size:12px;vertical-align:baseline;color:rgba(0,0,0,1);">목표주가: 610,000원(상향)</span></div>
<div class="txt" style="position:absolute; left:38px; top:237px;"><span id="f2" style="font-size:12px;vertical-align:baseline;color:rgba(85,146,206,1);">Abbvie와의 특허소송 합의로 2018년 10월 임랄디 출시 가능</span></div>
<div class="txt" style="position:absolute; left:38px; top:254px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스의 자회사 바이오에피스는 2018년 4월 5일 Humira의 특허권을</span></div>
<div class="txt" style="position:absolute; left:38px; top:270px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">가진 Abbvie와의 특허분쟁을 라이선스 계약 체결을 통해 합의했다. 이에 따라 바</span></div>
<div class="txt" style="position:absolute; left:38px; top:286px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">이오에피스는 류마티스 관절염 치료제 Humira의 바이오시밀러 임랄디를 Abbvie</span></div>
<div class="txt" style="position:absolute; left:38px; top:302px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">에 로열티를 지불하는 방식으로 2018년 10월부터 유럽에서 판매할 수 있게 됐다.</span></div>
<div class="txt" style="position:absolute; left:38px; top:318px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">유럽 내 판매는 Biogen이 담당한다. Humira는 2018년 10월 물질특허 기간이 만</span></div>
<div class="txt" style="position:absolute; left:38px; top:334px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">료될 예정이었지만 Abbvie가 같은 물질의 적응증 투여방법 특허를 추가해 류마티</span></div>
<div class="txt" style="position:absolute; left:38px; top:350px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">스 관절염 적응증은 2022년, 건선 적응증은 2023년으로 특허기간을 연장한 바</span></div>
<div class="txt" style="position:absolute; left:38px; top:366px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">있다. 이에 바이오에피스는 지난해 8월 유럽에서 임랄디의 판매허가를 받고 영국,</span></div>
<div class="txt" style="position:absolute; left:38px; top:382px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">네덜란드 등에서 Abbvie가 보유한 일부 특허에 대해 무효소송을 제기했다.</span></div>
<div class="txt" style="position:absolute; left:38px; top:413px;"><span id="f2" style="font-size:12px;vertical-align:baseline;color:rgba(85,146,206,1);">성공이 보장된 유럽에서 세계판매 1위 Humira 시밀러의 first-mover</span></div>
<div class="txt" style="position:absolute; left:38px; top:430px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">셀트리온의 램시마, 바이오에피스의 베네팔리를 통해 확인했듯이 유럽시장에서는</span></div>
<div class="txt" style="position:absolute; left:38px; top:446px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">first-mover 바이오시밀러의 성공이 어느정도 보장돼 있다. 임랄디는 경쟁사</span></div>
<div class="txt" style="position:absolute; left:38px; top:462px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Amgen의 Amjevita(2017년 3월 유럽 판매승인)와 공동으로 유럽에서 Humira</span></div>
<div class="txt" style="position:absolute; left:38px; top:478px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">시밀러의 first-mover가 될 예정이다. Humira는 2017년 글로벌 바이오의약품</span></div>
<div class="txt" style="position:absolute; left:38px; top:494px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">매출 1위(189억달러) 품목이다. 유럽 내 매출은 61억달러로 추정된다. 바이오에</span></div>
<div class="txt" style="position:absolute; left:38px; top:510px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">피스가 유럽에서 판매하고 있는 품목들의 오리지네이터인 Enbrel(14억달러)과</span></div>
<div class="txt" style="position:absolute; left:38px; top:526px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Remicade(8억달러)를 매출규모에서 압도하는 블록버스터다. 따라서 임랄디는</span></div>
<div class="txt" style="position:absolute; left:38px; top:542px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Amjevita와 동시에 출시되더라도 바이오에피스 제품들 중 가장 높은 peak</span></div>
<div class="txt" style="position:absolute; left:38px; top:558px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">sales(10억달러)를 달성하며 바이오에피스의 실적개선을 견인할 것이다.</span></div>
<div class="txt" style="position:absolute; left:412px; top:240px;"><span id="f2" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">Stock Data</span></div>
<div class="txt" style="position:absolute; left:412px; top:252px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">KOSPI(4/6)</span></div>
<div class="txt" style="position:absolute; left:542px; top:252px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">2,430</span></div>
<div class="txt" style="position:absolute; left:412px; top:263px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주가(4/6)</span></div>
<div class="txt" style="position:absolute; left:535px; top:263px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">519,000</span></div>
<div class="txt" style="position:absolute; left:412px; top:275px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">시가총액(십억원)</span></div>
<div class="txt" style="position:absolute; left:539px; top:275px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">34,340</span></div>
<div class="txt" style="position:absolute; left:412px; top:286px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">발행주식수(백만)</span></div>
<div class="txt" style="position:absolute; left:551px; top:286px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">66</span></div>
<div class="txt" style="position:absolute; left:412px; top:297px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">52주 최고/최저가(원)</span></div>
<div class="txt" style="position:absolute; left:511px; top:297px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">519,000/173,500</span></div>
<div class="txt" style="position:absolute; left:412px; top:309px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">일평균거래대금(6개월, 백만원)</span></div>
<div class="txt" style="position:absolute; left:535px; top:309px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">104,949</span></div>
<div class="txt" style="position:absolute; left:412px; top:320px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">유동주식비율/외국인지분율(%)</span></div>
<div class="txt" style="position:absolute; left:531px; top:320px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">21.8/10.5</span></div>
<div class="txt" style="position:absolute; left:412px; top:332px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주요주주(%) 삼성물산 외 4 인</span></div>
<div class="txt" style="position:absolute; left:545px; top:332px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">75.1</span></div>
<div class="txt" style="position:absolute; left:412px; top:365px;"><span id="f2" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">주가상승률</span></div>
<div class="txt" style="position:absolute; left:412px; top:389px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">절대주가(%)</span></div>
<div class="txt" style="position:absolute; left:412px; top:400px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">KOSPI 대비(%p)</span></div>
<div class="txt" style="position:absolute; left:412px; top:422px;"><span id="f2" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">주가추이</span></div>
<div class="txt" style="position:absolute; left:430px; top:440px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(천원)</span></div>
<div class="txt" style="position:absolute; left:414px; top:445px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">600</span></div>
<div class="txt" style="position:absolute; left:414px; top:460px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">500</span></div>
<div class="txt" style="position:absolute; left:414px; top:475px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">400</span></div>
<div class="txt" style="position:absolute; left:414px; top:490px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">300</span></div>
<div class="txt" style="position:absolute; left:414px; top:504px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">200</span></div>
<div class="txt" style="position:absolute; left:414px; top:519px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">100</span></div>
<div class="txt" style="position:absolute; left:424px; top:526px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">Apr-16</span></div>
<div class="txt" style="position:absolute; left:412px; top:540px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">자료: WISEfn</span></div>
<div class="txt" style="position:absolute; left:485px; top:378px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">1개월</span></div>
<div class="txt" style="position:absolute; left:488px; top:389px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">15.6</span></div>
<div class="txt" style="position:absolute; left:488px; top:400px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">14.8</span></div>
<div class="txt" style="position:absolute; left:514px; top:378px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">6개월</span></div>
<div class="txt" style="position:absolute; left:517px; top:389px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">53.8</span></div>
<div class="txt" style="position:absolute; left:517px; top:400px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">52.3</span></div>
<div class="txt" style="position:absolute; left:539px; top:378px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">12개월</span></div>
<div class="txt" style="position:absolute; left:542px; top:389px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">186.7</span></div>
<div class="txt" style="position:absolute; left:542px; top:400px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">173.9</span></div>
<div class="txt" style="position:absolute; left:478px; top:526px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">Apr-17</span></div>
<div class="txt" style="position:absolute; left:533px; top:526px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">Apr-18</span></div>
<div class="txt" style="position:absolute; left:38px; top:589px;"><span id="f2" style="font-size:12px;vertical-align:baseline;color:rgba(85,146,206,1);">바이오에피스의 가치를 재평가하며 목표주가를 61만원으로 상향</span></div>
<div class="txt" style="position:absolute; left:38px; top:606px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스에 대해 매수 투자의견을 유지하며 목표주가는 53만원에서 61</span></div>
<div class="txt" style="position:absolute; left:38px; top:622px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">만원으로 15% 상향한다. 임랄디 출시에 따른 실적개선을 반영해 바이오에피스의</span></div>
<div class="txt" style="position:absolute; left:38px; top:638px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">지분가치를 2.5조원에서 6.8조원으로 재산출했기 때문이다. 3공장 수주와 바이오</span></div>
<div class="txt" style="position:absolute; left:38px; top:654px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">에피스의 흑자전환에 따른 이익기여에 대한 기대감으로 삼성바이오로직스에 대해</span></div>
<div class="txt" style="position:absolute; left:38px; top:670px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">긍정적인 시각을 유지한다.</span></div>
<div class="txt" style="position:absolute; left:38px; top:722px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2016A</span></div>
<div class="txt" style="position:absolute; left:38px; top:734px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2017A</span></div>
<div class="txt" style="position:absolute; left:38px; top:745px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2018F</span></div>
<div class="txt" style="position:absolute; left:38px; top:756px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2019F</span></div>
<div class="txt" style="position:absolute; left:38px; top:768px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2020F</span></div>
<div class="txt" style="position:absolute; left:77px; top:700px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">매출액 영업이익 순이익 EPS 증감률 EBITDA PER </span><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">EV/EBITDA </span><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">PBR ROE DY</span></div>
<div class="txt" style="position:absolute; left:72px; top:711px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(십억원) (십억원) (십억원)</span></div>
<div class="txt" style="position:absolute; left:180px; top:711px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(원)</span></div>
<div class="txt" style="position:absolute; left:211px; top:711px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(%) (십억원) (x)</span></div>
<div class="txt" style="position:absolute; left:309px; top:711px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x) (x) (%) (%)</span></div>
<div class="txt" style="position:absolute; left:85px; top:722px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">295</span></div>
<div class="txt" style="position:absolute; left:118px; top:722px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(30) (177) (3,115)</span></div>
<div class="txt" style="position:absolute; left:212px; top:722px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:249px; top:722px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">30 NM</span></div>
<div class="txt" style="position:absolute; left:300px; top:722px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">320.6 2.4 (5.2) -</span></div>
<div class="txt" style="position:absolute; left:85px; top:734px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">465</span></div>
<div class="txt" style="position:absolute; left:123px; top:734px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">66 (97) (1,466)</span></div>
<div class="txt" style="position:absolute; left:212px; top:734px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:246px; top:734px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">136 NM</span></div>
<div class="txt" style="position:absolute; left:300px; top:734px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">181.7 6.2 (2.4) -</span></div>
<div class="txt" style="position:absolute; left:85px; top:745px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">532</span></div>
<div class="txt" style="position:absolute; left:123px; top:745px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">56</span></div>
<div class="txt" style="position:absolute; left:150px; top:745px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">491 7,422</span></div>
<div class="txt" style="position:absolute; left:212px; top:745px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:246px; top:745px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">144 69.9</span></div>
<div class="txt" style="position:absolute; left:300px; top:745px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">235.6 7.7 11.6 -</span></div>
<div class="txt" style="position:absolute; left:85px; top:756px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">968</span></div>
<div class="txt" style="position:absolute; left:119px; top:756px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">348</span></div>
<div class="txt" style="position:absolute; left:150px; top:756px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">307 4,633 (37.6)</span></div>
<div class="txt" style="position:absolute; left:246px; top:756px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">470 112.0</span></div>
<div class="txt" style="position:absolute; left:303px; top:756px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">71.3 7.0 6.5 -</span></div>
<div class="txt" style="position:absolute; left:79px; top:768px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">1,406</span></div>
<div class="txt" style="position:absolute; left:119px; top:768px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">682</span></div>
<div class="txt" style="position:absolute; left:150px; top:768px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">655 9,904 113.8</span></div>
<div class="txt" style="position:absolute; left:246px; top:768px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">804 52.4</span></div>
<div class="txt" style="position:absolute; left:303px; top:768px;"><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">41.0 6.2 12.5 -</span></div>
<div class="txt" style="position:absolute; left:412px; top:712px;"><span id="f2" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">진홍국</span></div>
<div class="txt" style="position:absolute; left:412px; top:728px;"><span id="f1" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">hg.jin@truefriend.com</span></div>
<div class="txt" style="position:absolute; left:412px; top:746px;"><span id="f2" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">정은영</span></div>
<div class="txt" style="position:absolute; left:412px; top:762px;"><span id="f1" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">eunice.jung@truefriend.com</span></div>
</body>
</html>
